drugset / Trial / NCT00559247
A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-650032 in subjects with chronic hepatitis C infection
Timeline
- Start
- 2008-01
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asunaprevir | Small molecule | 2.5 mg | Oral |
| Subject | Asunaprevir | Small molecule | 10 mg | Oral |
| Subject | Asunaprevir | Small molecule | 50 mg | Oral |
| Subject | Asunaprevir | Small molecule | 200 mg | Oral |
| Subject | Asunaprevir | Small molecule | 600 mg | Oral |